Aufklappen
Schliessen
Branche BiotechnologieAktienmarkt Sonstige |
|
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
| Leser | Medien | |
|---|---|---|---|---|
| Fr | XFRA B9A: WIEDERAUFNAHME/RESUMPTION | 3 | Xetra Newsboard | |
| FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE. THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE: INSTRUMENT... ► Artikel lesen | ||||
| Fr | Nasdaq Stockholm AB: Lift of Suspension in BioArctic AB at XSTO (39/19) | 9 | GlobeNewswire | |
| Lifting of Suspension
At Trading Venue XSTO
Issuer: BioArctic AB, LEI: 549300Y0OI2WVUNHLC33
--------------------------------------------------------------------------------
Instrument:... ► Artikel lesen | ||||
| BIOARCTIC Aktien ab 5,80 Euro handeln - Ohne versteckte Kosten! | LYNX | |||
► Artikel lesen | ||||
| Fr | BioArctic's Partner Eisai Initiates the Confirmatory Phase 3 Study of BAN2401 in Early Alzheimer's Disease | 13 | PR Newswire | |
| STOCKHOLM, Sweden, March 21, 2019 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that its partner Eisai has initiated the global Phase 3 confirmatory study... ► Artikel lesen | ||||
| Do | XFRA B9A: AUSSETZUNG/SUSPENSION | 3 | Xetra Newsboard | |
| DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT: THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL BIOARCTIC AB... ► Artikel lesen | ||||
| 14.03. | BioArctic Announces Start of Phase 1 Study of ABBV-0805 for Parkinson's Disease | 5 | PR Newswire | |
| STOCKHOLM, March 13, 2019 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the first clinical study with ABBV-0805 has started in the U.S. AbbVie is responsible... ► Artikel lesen | ||||
| 07.03. | BioArctic: Eisai Announces Timelines for the Single Confirmatory Phase 3 Study With BAN2401 in Warly Alzheimer's Disease | 16 | PR Newswire | |
| STOCKHOLM, March 7, 2019 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) informs that Eisai today announced the timelines for the single confirmatory Phase 3 study with... ► Artikel lesen | ||||
| 14.02. | BioArctic - Full Year Report January - December 2018 | 5 | PR Newswire | |
| STOCKHOLM, Feb. 14, 2019 /PRNewswire/ --
BioArctic's partner Eisai will initiate BAN2401 confirmatory Phase 3-study in early Alzheimer's disease. AbbVie in-licensed the Parkinson portfolio
October... ► Artikel lesen | ||||
| 13.02. | BioArctic's Product Candidate SC0806 for Treatment of Patients With Complete Spinal Cord Injury is now in Phase 2 | 2 | PR Newswire | |
| STOCKHOLM, Feb. 13, 2019 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the first patient in the second panel of the Phase 1/2 study now has been treated... ► Artikel lesen | ||||
| 11.02. | BioArctic Says FDA Approved IND for ABBV-0805, In-Licensed by AbbVie (ABBV) | 2 | StreetInsider.com | |
► Artikel lesen | ||||
| 11.02. | BioArctic: U.S. Food and Drug Administration Approves Investigational New Drug Applicationfor ABBV-0805 | 6 | PR Newswire | |
| ABBV-0805 is being evaluated as a potential disease modifying treatment for Parkinson's Disease
STOCKHOLM, Feb. 11, 2019 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B)... ► Artikel lesen | ||||
| 04.02. | BioArctic Announces That Eisai Will Initiate Phase 3 Confirmatory Study With BAN2401 in Early Alzheimer's Disease | 12 | PR Newswire | |
| STOCKHOLM, Feb. 4, 2019 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that Eisai stated at their Q3 FY2018 Financial Results Meeting on February 4, 2019 that... ► Artikel lesen | ||||
| 14.12.18 | BioArctic Outlicenses its Alpha-synuclein Antibody Portfolio for Parkinson's Disease to AbbVie After Receiving Clearance | 39 | PR Newswire | |
| STOCKHOLM, Dec. 14, 2018 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that BioArctic and its partner AbbVie (NYSE: ABBV) have received U.S. Federal Trade... ► Artikel lesen | ||||
| 12.11.18 | BioArctic is Awarded Grant From EU's Horizon 2020 for Participation in Research Consortium for Better Diagnostic Tools and Biomarkers for Parkinson's | 6 | PR Newswire | |
| STOCKHOLM, Nov. 12, 2018
/PRNewswire/ --
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) has been awarded a grant from EU's research and innovation program Horizon 2020. The grant... ► Artikel lesen | ||||
| 02.11.18 | BioArctic's Partner AbbVie Exercises its Option to License the Alpha-synuclein Antibody Portfolio for Parkinson's Disease | 23 | PR Newswire | |
| STOCKHOLM, Oct. 2, 2018 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company has received a Notice of Option Exercise under the Research, Development... ► Artikel lesen | ||||
| 02.11.18 | XFRA FRA:New Instruments available on XETRA - 02.11.2018-002 | 20 | Xetra Newsboard | |
| The following instruments on XETRA do have their first trading day 02.11.2018 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag am 02.11.2018 TrdMod InstCode Exch ISIN Name InstGrp InstType... ► Artikel lesen | ||||
| 25.10.18 | BioArctic Announces Additional BAN2401 Phase 2b Study Results in Early Alzheimer's Disease Presented by Eisai at the 2018 CTAD Conference | 7 | PR Newswire | |
| STOCKHOLM, Oct. 25, 2018 /PRNewswire/ --
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) previously announced on July 6, 2018 the positive topline results from the clinical Phase 2b study... ► Artikel lesen | ||||
| 21.10.18 | BioArctic is Granted a Concept Patent in Europe for the Company's Strategy for Disease-modifying Treatment of Parkinson's Disease | 10 | PR Newswire | |
| STOCKHOLM, Oct. 21, 2018 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA-B) announced today that the European Patent Office (EPO) has issued a decision to grant the company's... ► Artikel lesen | ||||
| 03.10.18 | BioArctic Receives European Patent Protection for a Medical Device for Treatment of Patients with Complete Spinal Cord Injury | 4 | PR Newswire | |
| STOCKHOLM, Oct. 3, 2018 /PRNewswire/ --
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the European Patent Office (EPO) has issued a decision to grant the company's... ► Artikel lesen | ||||
| 13.09.18 | BioArctic SIgns a Research Agreement With Brain Biomarker Solutions in Gothenburg AB to Develop New Diagnostics for Alzheimer's Disease | 5 | PR Newswire | |
| STOCKHOLM, Sweden, Sept. 13, 2018 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) has signed a research agreement with Brain Biomarker Solutions in Gothenburg AB (BBS). BBS... ► Artikel lesen | ||||
| 03.09.18 | BioArctic Expands the Research Collaboration With Uppsala University Concerning Antibody-based Diagnostic Imaging of the Brain in Alzheimer Patients | 6 | PR Newswire | |
| STOCKHOLM, Sept. 3, 2018 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announces that the company has signed an expanded research collaboration agreement with Uppsala... ► Artikel lesen | ||||
Seite:
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten:
VerkaufenHaltenKaufen
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | |
|---|---|---|---|---|
| EVOTEC | 21,95 | -0,14 % | Im Schatten von Evotec und Morphosys: Diese Aktie steigt wöchentlich um 10% | |
| Während der Anleger-Blick hierzulande hauptsächlich auf heimische TecDAX-Aktien gerichtet ist, befindet sich der hier vorgestellte, hochspezialisierte Medizingerätehersteller zur Diagnose und Behandlung... ► Artikel lesen | ||||
| MEDIGENE | 8,725 | -4,23 % | Medigene: Auf langfristigen Durchbruch setzen | |
| Kulmbach (www.aktiencheck.de) - Medigene-Aktienanalyse von André Fischer, Redakteur des Online-Anlegermagazins "Der Aktionär": André Fischer von "Der Aktionär" nimmt in einer aktuellen Aktienanalyse... ► Artikel lesen | ||||
| MORPHOSYS | 81,95 | -1,27 % | Leerverkäufer-Alarm! Starke Bewegung bei Steinhoff - deutlicher Aufbau bei Salzgitter AG und MorphoSys sowie Dürr und Aareal Bank - merklicher Abbau bei K+S und Nordex - insgesamt 13 Veränderungen! | |
| Hier finden Sie einen Überblick über die aktuellen Veränderungen bei den Leerverkaufspositionen deutscher Aktien am 15. März Seit geraumer Zeit sind die Aktien deutscher Unternehmen verstärkt ins Visier... ► Artikel lesen | ||||
| BB BIOTECH | 62,55 | -1,81 % | Biotech-Dividendenperle BB Biotech: Was Investoren zur Generalversammlung wissen sollten! | |
| Bei BB Biotech (WKN: A0NFN3) war es diese Woche so weit! Die Generalversammlung tagte und hat - so wie wir derzeit lesen können - alles durchgewinkt, was das Management der auf Biotech-Perlen spezialisierten... ► Artikel lesen | ||||
| QIAGEN | 35,04 | -1,41 % | QIAGEN supports World TB Day with major innovations in the fight against latent tuberculosis | |
| Developing new automation options for QuantiFERON-TB Gold Plus the modern blood-based test for TB detection and new QFT Access for high burden, low-resource regions QIAGEN N.V. (NYSE:... ► Artikel lesen | ||||
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und mit der Push-Technologie von
Nachrichten • Aktienkurse • DAX • Xetra-Orderbuch • Watchlist
Ad hoc-Mitteilungen • Nachrichten Börsen • Aktien-Empfehlungen
Branchen • Medien • Nachrichten-Archiv
Impressum | AGB | Disclaimer | Datenschutz • Presse • Mediadaten
RSS-News von FinanzNachrichten.de kostenlos für Ihren Browser und Ihre Homepage